Screening for antibodies against the ANNA-3 antigen is used in the investigation of patients with possible paraneoplastic syndrome.
ANNA-3 antigen is a rare paraneoplastic marker that has been detected in patients with small-cell lung cancer and in patients with lung and esophageal adenocarcinoma. Clinical symptoms include sensory-motor neuropathy with or without ataxia, cerebral ataxia, brainstem encephalomyopathy with sensory disorders. Antibodies may coexist with other paraneoplastic markers such as antibodies against Ri antigens (Nova-1) and calcium channels (VGCC).
See also: Anti-Neuronal Antibodies